Who are Adalimumab, current formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira, Abrilada, Switch to a second anti-TNF drug alone, CYCLOSPORINE VS INFLIXIMAB, daclizumab, infliximab, Infliximab [infliximab biosimilar 3].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adalimumab-current-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Adalimumab, current formulation — Competitive Intelligence Brief

Adalimumab, current formulation (Adalimumab, current formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

phase 2 TNF-alpha inhibitor TNF-alpha Immunology Biologic Live · refreshed every 30 min

Target snapshot

Adalimumab, current formulation (Adalimumab, current formulation) — AbbVie (prior sponsor, Abbott). Tumor necrosis factor-alpha inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adalimumab, current formulation TARGET	Adalimumab, current formulation	AbbVie (prior sponsor, Abbott)	phase 2	TNF-alpha inhibitor	TNF-alpha
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Switch to a second anti-TNF drug alone	Switch to a second anti-TNF drug alone	Védrines, Philippe, M.D.	marketed	TNF inhibitor (class-level; specific agent varies)	TNF-alpha
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)
daclizumab, infliximab	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha
Infliximab [infliximab biosimilar 3]	infliximab-infliximab-biosimilar-3	Pfizer	marketed	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

Abbott · 4 drugs in this class
Centre for Human Drug Research, Netherlands · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 2 drugs in this class
Alvotech Swiss AG · 2 drugs in this class
UCB Pharma · 2 drugs in this class
Celltrion · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
Asan Medical Center · 1 drug in this class
Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adalimumab, current formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-current-formulation. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab